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Background. Severity of human metapneumovirus (hMPV) lower respiratory illness (LRTI) is considered similar to that ob-
served for respiratory syncytial virus (RSV). However, differences in severity between these pathogens have been noted, suggesting 
the degree of illness may vary in different populations. Moreover, a potential association between hMPV and asthma also suggests 
that hMPV may preferentially affect asthmatic subjects.
Methods. In a population-based surveillance study in children aged <2 years admitted for severe LRTI in Argentina, nasopha-
ryngeal aspirates were tested by RT-PCR for hMPV, RSV, influenza A, and human rhinovirus.
Results. Of 3947 children, 383 (10%) were infected with hMPV. The hospitalization rate for hMPV LRTI was 2.26 per 1000 
children (95% confidence interval [CI], 2.04–2.49). Thirty-nine (10.2%) patients infected with hMPV experienced life-threatening 
disease (LTD; 0.23 per 1000 children; 95% CI, .16–.31/1000), and 2 died (mortality rate 0.024 per 1000; 95% CI, .003–.086). In 
hMPV-infected children birth to an asthmatic mother was an increased risk for LTD (odds ratio, 4.72; 95% CI, 1.39–16.01). We ob-
served a specific interaction between maternal asthma and hMPV infection affecting risk for LTD.
Conclusions. Maternal asthma increases the risk for LTD in children <2 years old hospitalized for severe hMPV LRTI.
Keywords. human metapneumovirus; burden of illness; children; lower respiratory tract infection; risk factors; maternal asthma.
Lower respiratory tract illness (LRTI) due to respiratory vir-
uses is the leading cause of hospitalization in infants and 
young children worldwide [1, 2]. Human metapneumovirus 
(hMPV) is a frequent pediatric pathogen, associated with 
5%–25% of all cases of LRTI [3–6]. As with other pathogens, 
its burden is higher in developing countries and low-income 
populations [7–9].
The clinical presentation and virulence of hMPV LRTI in in-
fants and young children resembles that of other viruses, in-
cluding respiratory syncytial virus (RSV), being also capable 
of eliciting life-threatening disease (LTD) [10, 11]. That is why, 
in the context of the changing landscape of new interventions 
against RSV, it is important to understand how hMPV disease 
behaves in children and identify novel, preventable risk factors 
for severe disease.
Previously known risk factors for poor clinical evolution in 
children hospitalized for hMPV LRTI, such as prematurity, con-
genital heart disease, immunodeficiency, and neuromuscular 
disease, are not hMPV specific [3, 12–15]. Considering that the 
pattern of T-helper 2 (Th2) cytokines observed in respiratory 
secretions during hMPV LRTI may sometimes resemble that of 
individuals with asthma (including eosinophilic inflammation, 
higher interleukin-4 [IL-4] and IL-5 levels in mouse models 
[16], and induction of thymic stromal lymphopoietin in human 
airway cells [17, 18]) we speculated that a history of asthmatic 




We conducted a prospective, multicenter active surveillance 
study to characterize the burden of severe LRTI in children 
from a low-income region in Buenos Aires, Argentina from 
2011 to 2013. Details of the population are provided else-
where [19]. The study was held in 12 public hospitals, from a 
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geographically defined low-income region in the Buenos Aires 
suburbs, that provide care to an estimated population of 56 560 
children younger than 2  years who lacked medical insurance 
[20]. Previous studies in this population examined RSV LRTI 
severity and the role of cytokines in human rhinovirus (hRV) 
infections [19, 21–25]. The study was approved by institutional 
review boards at each participating hospital, the state of Buenos 
Aires, and Vanderbilt University. All participating families 
signed an informed consent to join the study.
Eligibility criteria included infants and children younger 
than 2 years admitted for severe LRTI, defined as the sudden 
onset of cough, wheezing, retractions and/or crackles, with or 
without fever, and an oxygen saturation <93% when breathing 
room air or the need for O2 support on arrival to emergency 
rooms. LTD was defined as O2 saturation ≤87% on admission, 
requirement for mechanical ventilation, and/or admission to 
the intensive care unit.
Demographic and Clinical Information
Information on demographic, epidemiological, and clinical 
status was recorded from all participating patients from the 
time of admission until discharge using specifically designed 
questionnaires. In the study, we evaluated risk factors for hospi-
talization including prematurity (<37 weeks’ gestation at birth), 
age, sex, lack of breastfeeding, malnutrition, house and floor 
materials, smoking at home, sources of heating, crowding (de-
fined as more than 3 persons/room), parent’s education, and 
availability of sewage system. Maternal asthma was defined as 
a physician diagnosis of asthma in the mother before infant 
enrollment.
Laboratory Tests
Nasopharyngeal aspirates were collected at the time of ad-
mission in patients from consenting families. Samples were 
tested in duplicate by real-time reverse transcriptase pol-
ymerase chain reaction (RT-PCR) for hMPV. Samples were 
also tested for influenza A viruses, RSV, and hRV, as previ-
ously described [19].
Statistical Analysis
Rates of severe and life-threatening hMPV disease were cal-
culated by dividing the number of patients hospitalized with 
hMPV severe respiratory infection by the estimated census an-
nual population in the selected area [20]. Student t test and χ2 
were used to compare children’s clinical and epidemiological 
characteristics when appropriate. For the evaluation of risk fac-
tors associated with hMPV LTD, we used a multivariable lo-
gistic regression model. Covariates selected a priori and with a 
P value < .1 in univariate analysis were included in the model 
and analyzed in a stepwise forward logistic regression. A  P 
value of less than .05 was considered statistically significant. 
Statistical analyses were performed using the Stata package for 
IBM-PC (Stata Corp).
RESULTS
Burden of Human Metapneumovirus LRTI
A total of 4045 hospitalized infants and young children met 
inclusion criteria; 3947 (98%) agreed to participate in the 
study. Clinical manifestations on admission were similar for 
participating and nonparticipating children (not shown). 
hMPV was detected in 383 (10%) children. Of these, 75 (20% 
of hMPV infections) were coinfected with RSV, 64 (17%) with 
hRV, and 1 with influenza A. Six patients were simultaneously 
infected with hMPV, RSV, and hRV. hMPV cases were more fre-
quent during the first year of the study and always followed the 
same seasonal pattern as RSV with a distinct midwinter peak 
(Figure 1). In each year, RSV was the virus most frequently de-
tected in study participants.
Among the 383 hMPV-infected children, 84% were younger 
than 1 year with a mean age on admission of 7.4 months (SD, 
5.08); 56% were boys. The rate of hospitalization for hMPV 
LRTI was 3.8 per 1000 infants (95% CI, 3.4–4.2) and 2.26 
per 1000 children younger than 2  years (95% CI, 2.04–2.49). 
Among all hMPV-infected patients, 39 (10.2%) experienced 
LTD (0.23 per 1000 children; 95% CI, .16–.31/1000). The mean 
age for LTD was 6.0 months (SD, 3.9; P = .08 vs ward admis-
sions) (Figure 2). Two boys died at 3 and 9 months of age due to 
hMPV, for a case-fatality ratio of 0.52% (95% CI, .06–1.87) and 
an infant hMPV mortality rate of 0.024 per 1000 (95% CI, .003–
.086). Both children had no previously known comorbidities 
and died due to septic shock and respiratory failure, respec-
tively. Compared to other viral etiologies, even when no virus 
was isolated, hMPV-associated case-fatality ratio appeared to 
be lower (RSV, 0.9% [95% CI, .44–1.35)]; hRV, 0.86% [95% CI, 
.17–2.5]; influenza A, 0.96% ([95% CI, .02–5.2]; and no virus 
detected, 0.68% [95% CI, .27–1.39]).
Children with hMPV coinfections with RSV, influenza, 
or hRV experienced more severe clinical signs on admission 
(tachypnea, tachycardia, wheezing, and chest retractions) than 
hMPV infections alone. However, coinfections did not increase 
the risk of LTD (Table 1). In comparison to patients with RSV 
LRTI, hMPV-infected hospitalized patients were significantly 
older (OR, 1.05; 95% CI, 1.02–1.07), breastfed less frequently 
(OR, 0.67; 95% CI, .46–.97), and were at lower risk of experien-
cing LTD (OR, 0.56; 95% CI, .36–.86) (Table 1).
A Subgroup of Infants at High Risk for Life-threatening hMPV LRTI
We subsequently explored whether children with hMPV (as a 
single pathogen or as a component of a coinfection) experienced 
disease of different severity than children infected with other 
viruses. Indeed, hMPV LRTI was milder in our population than 
disease elicited by RSV, hRV, and/or influenza A (OR, 0.53; 95% 
CI, .36–.79) (Figure 3). But even though disease associated with 
hMPV was generally milder, a subgroup of infected children 
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subpopulation with identifiable risk factors was disproportion-
ality represented in this subgroup of subjects.
Given the Th2 polarization in respiratory secretions [16–
18] and the reported association between hMPV hospitaliza-
tions and asthmatic children [12, 26, 27], we hypothesized 
that children of asthmatic mothers would be overrepresented 
among patients infected with the virus experiencing LTD. 
Indeed, the rate of hMPV LTD in children of asthmatic mothers 
was 277/1000 compared to children of nonasthmatic mothers 
whose hMPV LTD rate was 3.4 times lower at 82.3/1000 (OR, 
4.29; 95% CI, 1.42–12.93; P = .01 for LTD in children of asth-
matic mothers vs children born to nonasthmatic mothers). 
The observed effect for maternal asthma remained significant 






































































Figure 1. Viral circulation in infants and children 0–24 months of age during the study period. A, Number of hospitalized patients with human metapneumovirus (hMPV, 
solid line) lower respiratory tract illness (LRTI) in comparison to respiratory syncytial virus (RSV, dashed line), human rhinovirus (hRV, dotted line), and influenza A (dash dot 
line), per study year. B, Number of hospitalized patients with hMPV LRTI according to the epidemiological week during the 3 respiratory seasons (2011, solid line; 2012, 
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OR, 4.72; 95% CI, 1.39–16.01). Conversely, no increased risk 
was observed for maternal asthma in promoting LTD during 
RSV (OR, 1.4; 95% CI, .85–2.33), hRV (OR, 0.36; 95% CI, .07–
2.93), or influenza A  infections (OR, 1.33; 95% CI, .1–16.91) 
(Figure 4). Interestingly, when compared with patients with no 
virus detected as the control group, we observed that children 
admitted with hMPV infection and whose mothers were not 
asthmatic had a lowest risk of experiencing LTD (OR, 0.51; 95% 
CI, .33–.78; interaction P value = .024). However, when the 
mother was asthmatic, hMPV infection did not significantly 
increase the risk of having LTD compared to those without viral 
detections (Supplementary Table 1).
 Finally, given the rate of hMPV coinfections with RSV in our 
population (20% of hMPV infections), we explored whether 
hMPV played an instrumental role in the association between ma-
ternal asthma and LTD, or the effect was potentially attributable to 
effects of RSV. In the subgroup of children with hMPV infections 
in the absence of RSV (hMPV single infections and coinfections 
with hRV or influenza A), maternal asthma promoted LTD (OR, 
3.8; 95% CI, 1.12–12.88; P = .03). The impact of maternal asthma 
in RSV infections alone was, conversely, not significant.
DISCUSSION
Our study reveals 2 interesting features of hMPV LRTI. While 
the virus appears to elicit milder disease among hospitalized 
children than other agents, among children admitted with 
hMPV LRTI, those born to asthmatic mothers are at increased 
risk for LTD. Twenty-eight percent of hMPV-infected pa-
tients hospitalized with LRTI and born to asthmatic mothers 
experienced LTD, in comparison to only 8% hMPV-infected 
patients hospitalized and born to nonasthmatic mothers. If 
confirmed in other studies and populations, these observa-
tions would be of considerable public health importance, 
given that asthma is the most frequent chronic disease during 
pregnancy with rising prevalence, and is now between 10% 
and 12% [28, 29].
Whether the observed phenomenon is due to direct effects 
from the immune response or other dysregulations due to 
maternal asthma during pregnancy [30–32], or represents an 
early warning in young future asthmatics, needs further inves-
tigation. The immune response against hMPV is complex [4]. 
The virus has been reported to trigger Th2 cytokines through 
thymic stromal lymphopoietin, IL-4, IL-5, IL-13, and Th-17 re-
sponses via the release of IL-1β, IL-17, and IL-6 [17, 18, 33–35]. 
Interestingly, asthma and pregnancy itself also elicit a Th2 [28, 
36, 37] and Th17 [38–40] bias. In studies analyzing other health 
metrics, maternal asthma has been previously associated with 
poor maternal (gestational diabetes and placenta previa), peri-
natal (preterm birth, low birth weight, and preeclampsia), and 
neonatal (severe hRV LRTI, neonatal death, and hospitaliza-
tions) outcomes [28, 29].
As reported by other groups, our study also showed that pa-
tients admitted for hMPV LRTI with previous comorbidities 
and those with severe complications during hospitalization were 
at higher risk for LTD. These risk factors have been described 
before for hMPV and other respiratory viruses [3, 12–15].
Several reports describe coinfections between hMPV and other 
respiratory viruses, mainly with hRV and RSV [41]. As others and 




















Figure 2. Distribution of life-threatening disease (LTD) in patients with human metapneumovirus (hMPV) severe lower respiratory tract illness according to age. Number of 
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coinfections [42–44]. Perhaps this phenomenon is explained in 
part by “viral interference,” when one virus totally or partially 
blocks the replication of the other pathogen [45]. However, the 
role for hMPV as a coinfecting agent is still unclear and requires 
further study [46–48]. In a changing epidemiological landscape 
driven by preventive interventions against RSV, hMPV may soon 
Table 1. Epidemiological and Clinical Differences Between Human Metapneumovirus Single Infection, Human Metapneumovirus Coinfections, and 
Respiratory Syncytial Virus Single Infection
Variable
hMPV  
Single Infection  
(n = 235)
RSV  
Single Infection  
(n = 2204) P Valuea
hMPV  
Coinfections  
(n = 148) P Valueb
Infant variables      
 Age, mo, mean (SD) 7.7 (5.04) 6.3 (5.21) .0001 6.9 (5.13) .119
 Male 122 (55.36) 1209 (68.97) .378 90 (62.5) .054
 Prematurityc 34 (14.47) 272 (12.34) .350 15 (10.14) .219
 Low birth weightd 36 (15.32) 269 (12.21) .171 22 (14.86) .904
 Breastfeeding 199 (84.68) 1967 (89.25) .036 125 (84.46) .953
 Comorbiditiese 12 (5.11) 86 (3.9) .373 5 (3.38) .427
 Complete immunization schedulef 124 (57.14) 1257 (59.29) .427 79 (56.83) .722
 Assistance to day care 8 (3.56) 96 (4.47) .523 6 (4.2) .755
 Malnutritiong 2 (1.96) 25 (3.77) .365 2 (3.13) .637
 Atopyh 9 (4.02) 97 (4.55) .79 3 (2.14) .296
Familial variables      
 Siblings with asthma 33 (19.19) 299 (19.14) .628 27 (26.47) .144
 Paternal asthma 11 (4.93) 108 (5.3) .924 6 (4.29) .364
 Maternal asthma 12 (5.38) 118 (5.51) .279 6 (4.26) .91
 Current maternal smoking 61 (27.6) 561 (26.56) .818 34 (24.29) .698
 Current paternal smoking 48 (41.38) 637 (45.18) .672 28 (38.36) .866
Pregnancy variables      
 Intrauterine growth retardation 12 (5.53) 87 (4.15) .696 11 (7.91) .761
 Teenage mother 22 (9.36) 206 (9.35) .994 7 (4.73) .101
 Elderly mother 23 (9.79) 257 (11.66) .392 16 (10.81) .747
 Smoking during pregnancy 46 (20.44) 450 (20.82) .792 24 (17.02) .408
Socioeconomic variables      
 Crowding 125 (53.19) 1041 (47.23) .083 78 (52.7) .926
 Precarious homei 165 (70.21) 1528 (69.33) .780 100 (67.57) .585
 Low maternal educationj 28 (11.91) 295 (13.38) .528 19 (12.84) .789
Clinical features at admission      
 Tachypnea 57 (24.26) 572 (25.95) .572 54 (36.49) .011
 Tachycardia 53 (22.55) 520 (23.59) .721 51 (34.46) .011
 Wheezing 46 (19.57) 549 (24.91) .543 43 (29.05) .033
 Chest retractions 52 (22.13) 469 (21.28) .347 50 (33.78) .012
Clinical outcomes during admission      
 Pneumonia 21 (8.93) 146 (6.62) .184 7 (4.73) .13
 Pneumothorax 1 (.43) 17 (.77) .562 … …
 Sepsis 5 (2.13) 30 (1.36) .352 1 (.68) .291
 Life-threatening diseasek 25 (11.11) 370 (18.26) .008 14 (10.14) .773
Data are No. (%) except where indicated. In bold those P values < .05.
Abbreviations: hMPV, human metapneumovirus; hMPV coinfection, hMPV-positive patient coinfected either with RSV, human rhinovirus, or influenza A viruses; hMPV single infection, hMPV-
infected patient without coinfections; RSV, respiratory syncytial virus.
aP value: hMPV single infection versus RSV single infection.
bP value: hMPV single infection versus hMPV coinfections.
cPrematurity: <37 weeks of gestational age.
dLow birth weight: <2500 g at birth.
eComorbidities: severe neurologic disorder, congenital cardiopathy, hematologic disorder, or immunodeficiency.
fComplete immunization schedule: according to national immunization schedule, https://www.argentina.gob.ar/salud/vacunas.
gMalnutrition: % of the infant’s weight compared to that of a normal child (50th percentile of weight for age) of the same age under 90% according to World Health Organization child growth 
standards: http://www.who.int/childgrowth/standards/en.
hAtopy: physician-diagnosed allergic rhinitis or atopic dermatitis.
iPrecarious home: dirt floor, no sewage, heating unvented sources, lack of potable water, house material tin/mud.
jLow maternal education: incomplete primary school.






/jid/article/223/12/2072/5713478 by guest on 02 N
ovem
ber 2021
Maternal Asthma and Disease in Children • jid 2021:223 (15 june) • 2077
alter its role and overall importance as a childhood pathogen 
should viral replacement occur [49]. Targeting children of asth-
matic mothers for prophylaxis against hMPV may be a cost-effec-
tive strategy in the era of personalized medicine.
In addition, our study provides important disease burden in-
formation about hMPV. The hMPV infant hospitalization rate 
was surprisingly similar in our population to that in the United 
States, which is estimated at 2–4.9 per 1000 infants [5, 26], and 
is considerably lower than that of RSV in other countries [23]. 
Importantly, the hMPV case fatality ratio in hospital was almost 
half that reported for RSV in the same population, highlighting 
that, to date, RSV remains the most important target for pre-
vention [23].
Our study has limitations. First, because (as is the case for most 
studies) we did not analyze our samples for all other viruses, such 
as coronavirus or parainfluenza virus type 3, their effect on our 
observations is unknown. Second, given the age of our subjects 
and the prospective nature of this program, whether severity de-
pended causally on maternal disease versus infant atopy/asthma 
cannot be answered. Third, given the observational nature of our 
study design focused on generating new hypotheses, no adjust-
ment for multiple testing was performed. Additional research is 
needed to confirm the role of maternal asthma as a risk factor for 
severity in hMPV-infected children. However, our program also 
has significant strengths, including its prospective design and the 
evaluation of respiratory samples using state-of-the-art labora-
tory RT-PCR techniques. Furthermore, to our knowledge, this is 
the first population-based study seeking to define the burden of 
hMPV disease in a vulnerable population from a low- or middle-
income country. In addition, this large study addressed numerous 
prenatal and perinatal risk factors, examining how they modify 
the severity of infection.
In summary, we report a novel observation that may alter 
our thinking about severe hMPV infections and, if confirmed 
in other studies, require us to reformulate its prevention strat-
egies. hMPV represents a threat for life-threatening disease to 
young children born to asthmatic mothers.
Supplementary Data
Supplementary materials are available at The Journal of Infectious 
Diseases online. Consisting of data provided by the authors to 
benefit the reader, the posted materials are not copyedited and 
are the sole responsibility of the authors, so questions or com-
ments should be addressed to the corresponding author.
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INFANT Respiratory Network members: Gustavo Pellegrino, 
MD, Guadalupe Fernandez Gago, MD, Cecilia Pozzolo, MD, 







Figure 3. Multivariable analysis of risk for life-threatening disease (LTD) ac-
cording to infecting virus. Odds ratio with 95% confidence interval for LTD (O2 
saturation ≤ 87% on admission, requirement for mechanical ventilation, and/or ad-
mission to the intensive care unit) in infants and children 0–24 months of age hos-
pitalized for human metapneumovirus single virus or coinfection (hMPV), respiratory 
syncytial virus (RSV), human rhinovirus (hRV), influenza A single infections, and with 
no virus detected (no virus) lower respiratory tract illness.
Table 2. Multivariable Analysis of Risk Factors for Life-threatening 
Disease in Children Hospitalized With Human Metapneumovirus Infection
Risk Factors Multivariable Analysis
 OR (95% CI) P Value
Sewage 0.4 (.14–1.1) .076
Running water 0.7 (.29–1.72) .439
Age <6 mo on admission 2.22 (.93–5.27) .071
Comorbiditiesa 6.47 (1.55–27.00) .01
Breastfeeding 0.61 (.21–1.77) .360
Smoking during pregnancy 2.04 (.81–5.14) .129
Maternal asthma 4.72 (1.39–16.01) .013
Severe complicationsb 4.69 (1.65–13.37) .004
Abbreviations: CI, confidence interval; OR, odds ratio.
aComorbidities: severe neurologic disorder, congenital cardiopathy, hematologic disorder, 
or immunodeficiency.
bSevere complications: pneumonia, sepsis, pneumothorax, or apnea.









Figure 4. Multivariable analysis of risk for life-threatening disease (LTD) ac-
cording to infecting virus and maternal asthma status. Odds ratio with 95% 
confidence interval for LTD (O2 saturation ≤ 87% on admission, requirement for 
mechanical ventilation, and/or admission to the intensive care unit) in infants and 
children 0–24 months of age hospitalized for human metapneumovirus single virus 
or coinfection (hMPV), respiratory syncytial virus (RSV), human rhinovirus (hRV), in-
fluenza A single infections, and with no virus detected (no virus) lower respiratory 






/jid/article/223/12/2072/5713478 by guest on 02 N
ovem
ber 2021
2078 • jid 2021:223 (15 june) • Libster et al
Laura Castro, MD, Rodrigo Egues Almeida, MD, Beatriz 
Rebec, MD, Mariela Gonzalez, MD, Mariel Calvo, MD, Julieta 
Henrichsen, MD, Celina Nocito, MD, Guillermo Barbero, MD, 
Juan Ves Losada, MD, Angel Bonina, MD, Edgardo Flamenco, 
MD, Alberto Rodriguez Perez, MD, Alicia Kobylarz, MD, Mirta 
Raggio, MD, Graciela Schavlosky, MD, Adriana Caria, MD, 
Edgar Barboza, MD, and Gustavo Sastre, MD.
Financial support. This work was supported by the Bill and 
Melinda Gates Foundation (grant numbers OPP1018614 and 
OPP1157162 to F. P. P.).
Potential conflicts of interest. All authors: No reported con-
flicts of interest. All authors have submitted the ICMJE Form 
for Disclosure of Potential Conflicts of Interest. Conflicts that 
the editors consider relevant to the content of the manuscript 
have been disclosed.
References
1. Nair  H, Brooks  WA, Katz  M, et  al. Global burden of res-
piratory infections due to seasonal influenza in young 
children: a systematic review and meta-analysis. Lancet 
2011; 378(9807):1917–30. 
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute 
lower respiratory infections due to respiratory syncytial 
virus in young children: a systematic review and meta-
analysis. Lancet 2010; 375(9725):1545–55. 
3. Anderson EJ, Simões EA, Buttery JP, et al. Prevalence and char-
acteristics of human metapneumovirus infection among hos-
pitalized children at high risk for severe lower respiratory tract 
infection. J Pediatric Infect Dis Soc 2012; 1:212–22.
4. Laham  FR, Israele  V, Casellas  JM, et  al. Differential 
production of inflammatory cytokines in primary in-
fection with human metapneumovirus and with other 
common respiratory viruses of infancy. J Infect Dis 2004; 
189:2047–56.
5. Williams JV, Edwards KM, Weinberg GA, et al. Population-
based incidence of human metapneumovirus infection 
among hospitalized children. J Infect Dis 2010; 201:1890–8.
6. Boivin G, De Serres G, Côté S, et al. Human metapneumovirus 
infections in hospitalized children. Emerg Infect Dis 2003; 
9:634–40.
7. Gregianini  TS, Seadi  CF, Menegolla  I, et  al. Human 
metapneumovirus in southern Brazil. Rev Soc Bras Med 
Trop 2018; 51:30–8.
8. Breiman RF, Cosmas L, Njenga MK, et al. Severe acute res-
piratory infection in children in a densely populated urban 
slum in Kenya, 2007–2011. BMC Infect Dis 2015; 15:1–11.
9. Hastings  AK, Erickson  JJ, Schuster  JE, et  al. Role of type 
I  interferon signaling in human metapneumovirus path-
ogenesis and control of viral replication. J Virol 2015; 
89:4405–20.
10. Howard LM, Edwards KM, Zhu Y, et al. Clinical features of 
human metapneumovirus infection in ambulatory children 
aged 5–13 years. J Pediatric Infect Dis Soc 2018; 7:165–8.
11. Wolf DG, Greenberg D, Kalkstein D, et al. Comparison of 
human metapneumovirus, respiratory syncytial virus and 
influenza A virus lower respiratory tract infections in hospi-
talized young children. Pediatr Infect Dis J 2006; 25:320–4.
12. Estrada  B, Carter  M, Barik  S, Vidal  R, Herbert  D, 
Ramsey KM. Severe human metapneumovirus infection in 
hospitalized children. Clin Pediatr (Phila) 2007; 46:258–62.
13. Papenburg  J, Hamelin  MÈ, Ouhoummane  N, et  al. 
Comparison of risk factors for human metapneumovirus 
and respiratory syncytial virus disease severity in young 
children. J Infect Dis 2012; 206:178–89.
14. Scheuerman  O, Barkai  G, Mandelboim  M, Mishali  H, 
Chodick  G, Levy  I. Human metapneumovirus (hMPV) 
infection in immunocompromised children. J Clin Virol 
2016; 83:12–16. 
15. Hahn A, Wang W, Jaggi P, et al. Human metapneumovirus 
infections are associated with severe morbidity in hos-
pitalized children of all ages. Epidemiol Infect 2013; 
141:2213–23.
16. Hamelin ME, Couture C, Sackett MK, Boivin G. Enhanced 
lung disease and Th2 response following human 
metapneumovirus infection in mice immunized with the 
inactivated virus. J Gen Virol 2007; 88:3391–400.
17. Li Y, Lund C, Nervik I, et al. Characterization of signaling 
pathways regulating the expression of pro-inflammatory 
long form thymic stromal lymphopoietin upon human 
metapneumovirus infection. Sci Rep 2018; 8:883.
18. Lay  MK, Céspedes  PF, Palavecino  CE, et  al. Human 
metapneumovirus infection activates the TSLP pathway 
that drives excessive pulmonary inflammation and viral 
replication in mice. Eur J Immunol 2015; 45:1680–95.
19. Ferolla  FM, Hijano  DR, Acosta  PL, et  al. Macronutrients 
during pregnancy and life-threatening respiratory syncy-
tial virus infections in children. Am J Respir Crit Care Med 
2013; 187:983–90.
20. Instituto Nacional de Estadística y Censos. Censo Nacional 
de Población, Hogares y Viviendas 2010. Argentino: 
Instituto Nacional de Estadística y Censos, 2015.
21. Caballero  MT, Hijano  DR, Acosta  PL, et  al; INFANT 
Respiratory Network. Interleukin-13 associates with life-
threatening rhinovirus infections in infants and young 
children. Pediatr Pulmonol 2018; 53:787–95.
22. Atwell  JE, Geoghegan  S, Karron  RA, Polack  FP. Clinical 
predictors of critical lower respiratory tract illness due to 
respiratory syncytial virus in infants and children: data to 







/jid/article/223/12/2072/5713478 by guest on 02 N
ovem
ber 2021
Maternal Asthma and Disease in Children • jid 2021:223 (15 june) • 2079
23. Geoghegan S, Erviti A, Caballero MT, et al. Mortality due 
to respiratory syncytial virus. burden and risk factors. Am J 
Respir Crit Care Med 2017; 195:96–103.
24. Rajan D, O’Keefe EL, Travers C, et al. MUC5AC levels asso-
ciated with respiratory syncytial virus disease severity. Clin 
Infect Dis 2018; 67:1441–4.
25. Libster  R, Ferolla  FM, Hijano  DR, Acosta  PL, Erviti  A, 
Polack FP; INFANT Respiratory Network. Alcohol during 
pregnancy worsens acute respiratory infections in children. 
Acta Paediatr 2015; 104:e494–9.
26. Edwards  KM, Zhu  Y, Griffin  MR, et  al; New Vaccine 
Surveillance Network. Burden of human metapneumovirus 
infection in young children. N Engl J Med 2013; 368:633–43.
27. Furuta T, Hasegawa S, Mizutani M, et al. Burden of human 
metapneumovirus and respiratory syncytial virus infec-
tions in asthmatic children. Pediatr Infect Dis J 2018; 
37:1107–11.
28. Murphy VE, Jensen ME, Gibson PG. Asthma during preg-
nancy: exacerbations, management, and health outcomes 
for mother and infant. Semin Respir Crit Care Med 2017; 
38:160–73.
29. Carroll  KN, Gebretsadik  T, Minton  P, et  al. Influence of 
maternal asthma on the cause and severity of infant acute 
respiratory tract infections. J Allergy Clin Immunol 2012; 
129:1236–42.
30. Rudd  PA, Thomas  BJ, Zaid  A, et  al. Role of human 
metapneumovirus and respiratory syncytial virus in asthma 
exacerbations: where are we now? Clin Sci (Lond) 2017; 
131:1713–21.
31. García-García  ML, Calvo  C, Casas  I, et  al. Human 
metapneumovirus bronchiolitis in infancy is an impor-
tant risk factor for asthma at age 5. Pediatr Pulmonol 2007; 
42:458–64.
32. Coverstone  AM, Wilson  B, Burgdorf  D, et  al. Recurrent 
wheezing in children following human metapneumovirus 
infection. J Allergy Clin Immunol 2018; 142:297–301.e2.
33. Liu  Y, Qin  T, Zhao  X, et  al. Skewed balance of regulatory 
T cell and inflammatory T cell in IL-17 defect with human 
metapneumovirus infection. Cell Immunol 2018; 331:161–7.
34. Park  JS, Kim  YH, Kwon  E, Callaway  Z, Fujisawa  T, 
Kim CK. Comparison of nasal cytokine profiles of human 
metapneumovirus and respiratory syncytial virus. Asia Pac 
Allergy 2017; 7:206–12.
35. González AE, Lay MK, Jara EL, et al. Aberrant T cell im-
munity triggered by human respiratory syncytial virus 
and human metapneumovirus infection. Virulence 2017; 
8:685–704.
36. Dietert RR. Maternal and childhood asthma: risk factors, inter-
actions, and ramifications. Reprod Toxicol 2011; 32:198–204.
37. Lim RH, Kobzik L. Maternal transmission of asthma risk. 
Am J Reprod Immunol 2009; 61:1–10.
38. Kaminski  V  de  L, Ellwanger  JH, Matte  MCC, Savaris  RF, 
Vianna P, Chies JAB. IL-17 blood levels increase in healthy 
pregnancy but not in spontaneous abortion. Mol Biol Rep 
2018; 45:1565–8.
39. Martínez-García  EA, Chávez-Robles  B, Sánchez-
Hernández PE, et al. IL-17 increased in the third trimester 
in healthy women with term labor. Am J Reprod Immunol 
2011; 65:99–103.
40. Santner-Nanan  B, Peek  MJ, Khanam  R, et  al. Systemic 
increase in the ratio between Foxp3+ and IL-17-producing 
CD4+ T cells in healthy pregnancy but not in preeclampsia. 
J Immunol 2009; 183:7023–30.
41. Fathima  S, Lee  BE, May-Hadford  J, Mukhi  S, Drews  SJ. 
Use of an innovative web-based laboratory surveillance 
platform to analyze mixed infections between human 
metapneumovirus (hMPV) and other respiratory viruses 
circulating in Alberta (AB), Canada (2009–2012). Viruses 
2012; 4:2754–65.
42. Moe N, Krokstad S, Stenseng IH, et al. Comparing human 
metapneumovirus and respiratory syncytial virus: viral 
codetections, genotypes and risk factors for severe disease. 
PLoS One 2017; 12:1–19.
43. Woensel  JBM  Van, Bos  AP, Lutter  R, Rossen  JWA, 
Schuurman  R. Absence of human metapneumovirus 
co-infection in cases of severe respiratory syncytial virus 
infection. Pediatr Pulmonol 2006; 41:872–4.
44. Lazar I, Weibel C, Dziura J, Ferguson D, Landry ML, Kahn JS. 
Human metapneumovirus and severity of respiratory syncy-
tial virus disease. Emerg Infect Dis 2004; 10:1318–20.
45. Schultz-Cherry S. Viral interference: the case of influenza 
viruses. J Infect Dis 2015; 212:1690–1.
46. Semple MG, Cowell A, Dove W, et al. Dual infection of in-
fants by human metapneumovirus and human respiratory 
syncytial virus is strongly associated with severe bronchio-
litis. J Infect Dis 2005; 191:382–6.
47. Foulongne  V, Guyon  G, Rodière  M, Segondy  M. Human 
metapneumovirus infection in young children hospital-
ized with respiratory tract disease. Pediatr Infect Dis J 2006; 
25:354–9.
48. Moattari A, Aleyasin S, Emami A, Fyruzi M, Pirbonyeh N. 
The prevalence of human metapneumovirus and respira-
tory syncytial virus and coinfection with both in hospital-
ized children with acute respiratory infection in south of 
Iran. Arch Pediatr Infect Dis 2015; 3:3–7.
49. Williams  J  V, Maitre  N. Human metapneumovirus in 







/jid/article/223/12/2072/5713478 by guest on 02 N
ovem
ber 2021
